StageIPO | IPO
Date of IPO10/8/2021
About Cognition Therapeutics
Cognition Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics that address the toxic oligomeric proteins that cause synapse degeneration and trigger neurodegenerative conditions such as Alzheimer's disease. The company was founded in 2007 and is based in Pittsburgh, Pennsylvania.
Missing: Cognition Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cognition Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cognition Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cognition Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cognition Therapeutics Patents
Cognition Therapeutics has filed 18 patents.
The 3 most popular patent topics include:
- Neurological disorders
- Cognitive disorders
- Alzheimer's disease
Neurological disorders, Alzheimer's disease, Clusters of differentiation, Cognitive disorders, Rare diseases
Neurological disorders, Alzheimer's disease, Clusters of differentiation, Cognitive disorders, Rare diseases
Latest Cognition Therapeutics News
May 23, 2023
and neuroinflammation. Importantly, these changes in key biomarkers were replicated across studies, and had similar directionality and degree of change. In this conversation, Dr. Charlotte Teunissen moderates a discussion on interpretation of these findings and their relevance to the CT1812 mechanism of action with two leading experts in biomarker development. Episode 5 : “Exploring the Effects of CT1812 on Alzheimer’s Disease Processes: Proteomics and Pathways of Neurodegeneration” features: Charlotte Teunissen, PhD - Professor of Clinical Neurochemistry at Amsterdam University Medical Center Nicholas Seyfried, PhD - Professor of Biochemistry and Neurology at Emory University School of Medicine and Director of the Emory Integrated Proteomics Core Henrik Zetterberg, MD, PhD - Professor of Neuroscience at Gothenburg University and Group Leader of the UK Dementia Research Institute Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at email@example.com. We’d love to hear your thoughts! About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com Health Care Disclaimer Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information:
Cognition Therapeutics Frequently Asked Questions (FAQ)
When was Cognition Therapeutics founded?
Cognition Therapeutics was founded in 2007.
Where is Cognition Therapeutics's headquarters?
Cognition Therapeutics's headquarters is located at 2403 Sidney Street, Pittsburgh.
What is Cognition Therapeutics's latest funding round?
Cognition Therapeutics's latest funding round is IPO.
How much did Cognition Therapeutics raise?
Cognition Therapeutics raised a total of $77.3M.
Who are the investors of Cognition Therapeutics?
Investors of Cognition Therapeutics include National Institute on Aging, Paycheck Protection Program, National Institute of Aging, Golden Seeds, Ogden CAP and 19 more.
Who are Cognition Therapeutics's competitors?
Competitors of Cognition Therapeutics include Carmot Therapeutics, Forma Therapeutics, DiscoveryBioMed, CellCentric, InterveXion Therapeutics and 9 more.
Compare Cognition Therapeutics to Competitors
Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.
Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.
Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.
Terpenoid Therapeutics is a drug discovery and development company focused on treatments for cancer. The company are developing a portfolio of small molecule- based compounds primarily for treatment of prostate, brease, brain, lung and colon cancers.
Transposagen Biopharmaceuticals is a biotechnology company. It develops and provides early gene editing technology for disease modeling, bioproduction, and phenotypic screening. The company serves the research needs of both academic and drug discovery investigators. It was founded in 2003 and is based in Lexington, Kentucky.
InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. The company are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.